References
1. Watson CJ. The ever‐expanding landscape of cancer therapeutic
approaches. Wiley Online Library; 2021. p. 6082-6.
2. WHO cancer regional profile [Internet]. World Health
Organization. 2020. Available from:
https://www.who.int/teams/noncommunicable-diseases/surveillance/data/cancer-profiles.
3. Farhood B, Geraily G, Alizadeh A. Incidence and Mortality of Various
Cancers in Iran and Compare to Other Countries: A Review Article. Iran J
Public Health. 2018;47(3):309-16.
4. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano
CM, et al. Cancer treatment and survivorship statistics, 2019. CA: A
Cancer Journal for Clinicians. 2019;69(5):363-85.
5. Kaliadzich Z, Zamaro A, Goubkin S, Koulchitsky S, Suziedelis K.
Possibilities of Minimization of Side Effects of Anticancer
Chemotherapy. J Cancer Sci Treatment. 2019;2(1):84-6.
6. Hauner K, Maisch P, Retz M. Side effects of chemotherapy. Der Urologe
Ausg A. 2017;56(4):472-9.
7. Hsu H-C, Tsai S-Y, Wu S-L, Jeang S-R, Ho M-Y, Liou W-S, et al.
Longitudinal perceptions of the side effects of chemotherapy in patients
with gynecological cancer. Supportive Care in Cancer.
2017;25(11):3457-64.
8. Berretta M, Della Pepa C, Tralongo P, Fulvi A, Martellotta F, Lleshi
A, et al. Use of Complementary and Alternative Medicine (CAM) in cancer
patients: An Italian multicenter survey. Oncotarget. 2017;8(15):24401.
9. Abdalla MEAH, Ali AM, Loong L. The use of complementary and
alternative medicine (CAM) among cancer patients at a tertiary hospital
in Malaysia. Complementary Therapies in Medicine. 2020;50:102343.
10. Toygar I, Yeşilbalkan ÖU, Kürkütlü M, Aslan A. Complementary and
alternative medicines used by cancer patients to cope with
chemotherapy-induced constipation. Complementary therapies in clinical
practice. 2020;39:101108.
11. Greener M. The hidden problem of herb‐drug interactions. Prescriber.
2016;27(9):22-7.
12. Labidi S, Ennouri S, Rachdi H, El Benna H, Mejri N, Daoud N, et al.
Use of complementary and alternative medicine in cancer: a Tunisian
single-center experience. Bulletin du cancer. 2020;107(2):209-14.
13. Wode K, Henriksson R, Sharp L, Stoltenberg A, Nordberg JH. Cancer
patients’ use of complementary and alternative medicine in Sweden: a
cross-sectional study. BMC complementary and alternative medicine.
2019;19(1):1-11.
14. Ong’udi M, Mutai P, Weru I. Study of the use of complementary and
alternative medicine by cancer patients at Kenyatta National Hospital,
Nairobi, Kenya. Journal of Oncology Pharmacy Practice.
2019;25(4):918-28.
15. Asiimwe JB, Nagendrappa PB, Atukunda EC, Kamatenesi MM, Nambozi G,
Tolo CU, et al. Prevalence of the Use of Herbal Medicines among Patients
with Cancer: A Systematic Review and Meta-Analysis. Evidence-Based
Complementary and Alternative Medicine. 2021;2021.
16. Engdal S, Steinsbekk A, Klepp O, Nilsen OG. Herbal use among cancer
patients during palliative or curative chemotherapy treatment in Norway.
Supportive Care in Cancer. 2008;16(7):763-9.
17. Cheng C-W, Fan W, Ko S-G, Song L, Bian Z-X. Evidence-based
management of herb-drug interaction in cancer chemotherapy. Explore.
2010;6(5):324-9.
18. Sweet E, Dowd F, Zhou M, Standish LJ, Andersen MR. The use of
complementary and alternative medicine supplements of potential concern
during breast cancer chemotherapy. Evidence-Based Complementary and
Alternative Medicine. 2016;2016.
19. Ramos-Esquivel A, Víquez-Jaikel Á, Fernández C. Potential drug-drug
and herb-drug interactions in patients with cancer: a prospective study
of medication surveillance. Journal of oncology practice.
2017;13(7):e613-e22.
20. Brantley SJ, Argikar AA, Lin YS, Nagar S, Paine MF. Herb–drug
interactions: challenges and opportunities for improved predictions.
Drug Metabolism and Disposition. 2014;42(3):301-17.
21. Oga EF, Sekine S, Shitara Y, Horie T. Pharmacokinetic herb-drug
interactions: insight into mechanisms and consequences. European journal
of drug metabolism and pharmacokinetics. 2016;41(2):93-108.
22. Awortwe C, Makiwane M, Reuter H, Muller C, Louw J, Rosenkranz B.
Critical evaluation of causality assessment of herb–drug interactions
in patients. British journal of clinical pharmacology.
2018;84(4):679-93.
23. Alsanad SM, Howard RL, Williamson EM. An assessment of the impact of
herb-drug combinations used by cancer patients. BMC complementary and
alternative medicine. 2016;16(1):1-9.
24. Alsanad SM, Williamson EM, Howard RL. Cancer patients at risk of
herb/food supplement–drug interactions: a systematic review.
Phytotherapy research. 2014;28(12):1749-55.
25. Meijerman I, Beijnen JH, Schellens JH. Herb‐drug interactions in
oncology: focus on mechanisms of induction. The oncologist.
2006;11(7):742-52.
26. Fasinu PS, Rapp GK. Herbal Interaction With Chemotherapeutic
Drugs—A Focus on Clinically Significant Findings. Frontiers in
oncology. 2019;9:1356.
27. Bazrafshani MS, Khandani BK, Pardakhty A, Tajadini H, Afshar RMP,
Moazed V, et al. The prevalence and predictors of using herbal medicines
among Iranian cancer patients. Complementary therapies in clinical
practice. 2019;35:368-73.
28. McIntyre E, Saliba AJ, Wiener KK, Sarris JJBc, medicine a. Herbal
medicine use behaviour in Australian adults who experience anxiety: a
descriptive study. 2016;16(1):1-12.
29. Hughes GD, Aboyade OM, Beauclair R, Mbamalu ON, Puoane TRJE-bc,
medicine a. Characterizing herbal medicine use for noncommunicable
diseases in urban South Africa. 2015;2015.
30. Azizah N, Halimah E, Puspitasari IM, Hasanah ANJJoMH. Simultaneous
use of herbal medicines and antihypertensive drugs among hypertensive
patients in the community: A review. 2021;14:259.
31. Wolf CP, Rachow T, Ernst T, Hochhaus A, Zomorodbakhsch B, Foller S,
et al. Complementary and alternative medicine (CAM) supplements in
cancer outpatients: analyses of usage and of interaction risks with
cancer treatment. Journal of Cancer Research and Clinical Oncology.
2021:1-13.
32. Bazrafshani MS, Khandani BK, Pardakhty A, Tajadini H, Afshar RMP,
Moazed V, et al. The prevalence and predictors of using herbal medicines
among Iranian cancer patients. 2019;35:368-73.
33. Welz AN, Emberger-Klein A, Menrad KJBc, medicine a. Why people use
herbal medicine: insights from a focus-group study in Germany.
2018;18(1):1-9.
34. Routledge PA, Bracchi RJADRB. Adverse drug reactions to herbal
medicines. 2021;331(1):1283-6.
35. Rosenkranz B, Fasinu P, Bouic PJFip. An overview of the evidence and
mechanisms of herb–drug interactions. 2012;3:69.
36. Başaran N, Paslı D, Başaran AAJF, Toxicology C. Unpredictable
adverse effects of herbal products. 2022;159:112762.
37. Oga EF, Sekine S, Shitara Y, Horie TJEjodm, pharmacokinetics.
Pharmacokinetic herb-drug interactions: insight into mechanisms and
consequences. 2016;41(2):93-108.
38. Parvez MK, Rishi VJCdm. Herb-drug interactions and hepatotoxicity.
2019;20(4):275-82.
39. Ramos-Esquivel A, Víquez-Jaikel Á, Fernández CJJoop. Potential
drug-drug and herb-drug interactions in patients with cancer: a
prospective study of medication surveillance. 2017;13(7):e613-e22.
40. Mahmoud D. The Prevalence of Clinically Relevant Herb-Drug
Interactions between Herbal Products and Anti-Cancer Therapy in Older
Adults with Cancer. 2021.
41. Citrin D, Gupta D, Birdsall T, Aslam A, Grutsch J, Wodek T, et al.
Prevalence of use of herbal therapies in adult cancer patients:
Potential for herb-drug interactions. 2005;23(16_suppl):6086-.
42. Van Leeuwen R, Brundel D, Neef C, van Gelder T, Mathijssen R, Burger
D, et al. Prevalence of potential drug–drug interactions in cancer
patients treated with oral anticancer drugs. 2013;108(5):1071-8.
43. Engdal S, Klepp O, Nilsen OGJIct. Identification and exploration of
herb-drug combinations used by cancer patients. 2009;8(1):29-36.
44. Ganzera M, Schneider P, Stuppner HJLs. Inhibitory effects of the
essential oil of chamomile (Matricaria recutita L.) and its major
constituents on human cytochrome P450 enzymes. 2006;78(8):856-61.
45. Blix HS, Viktil KK, Moger TA, Reikvam A. Drugs with narrow
therapeutic index as indicators in the risk management of hospitalised
patients. Pharmacy practice. 2010;8(1):50-5.
46. Teo YL, Ho HK, Chan AJBjocp. Metabolism‐related pharmacokinetic
drug− drug interactions with tyrosine kinase inhibitors: current
understanding, challenges and recommendations. 2015;79(2):241-53.
47. Dora NO, Blackburn E, Boles JE, Williams GT, White LJ, Turner SE, et
al. Supramolecular self-associating amphiphiles (SSAs) as nanoscale
enhancers of cisplatin anticancer activity. 2021;11(23):14213-7.
48. Ackland SP, Michael M, De Souza P, Martin JH, Clarke SJ, Francis K,
et al. Science and art of anticancer drug dosing: nine steps to
personalised therapy. 2020;50(8):992-6.
49. Darwich A, Ogungbenro K, Hatley OJ, Rostami-Hochaghan AJTCR. Role of
pharmacokinetic modeling and simulation in precision dosing of
anticancer drugs. 2017.
50. Haefeli WE, Carls AJEoodm, toxicology. Drug interactions with
phytotherapeutics in oncology. 2014;10(3):359-77.
51. Köhle C, Bock KWJBp. Coordinate regulation of human
drug-metabolizing enzymes, and conjugate transporters by the Ah
receptor, pregnane X receptor and constitutive androstane receptor.
2009;77(4):689-99.
52. Zanger UM, Schwab MJP, therapeutics. Cytochrome P450 enzymes in drug
metabolism: regulation of gene expression, enzyme activities, and impact
of genetic variation. 2013;138(1):103-41.
53. Tian D, Hu ZJCDM. CYP3A4-mediated pharmacokinetic interactions in
cancer therapy. 2014;15(8):808-17.
54. Fahim SM, Mishuk AU, Cheng N, Hansen R, Calderón AI, Qian JJEOoDS.
Adverse event reporting patterns of concomitant botanical dietary
supplements with CYP3A4 interactive & CYP3A4 non-interactive anticancer
drugs in the US Food and Drug Administration Adverse Event Reporting
System (FAERS). 2019;18(2):145-52.
55. Engdal S, Nilsen OGJPRAIJDtP, Derivatives TEoNP. In vitro inhibition
of CYP3A4 by herbal remedies frequently used by cancer patients.
2009;23(7):906-12.
56. Levy I, Attias S, Ben-Arye E, Goldstein L, Schiff EJI, medicine e.
Potential drug interactions with dietary and herbal supplements during
hospitalization. 2017;12(3):301-10.
57. Chi D, Ding D, Zhao Q, Liang X, Wu W, Luo J, et al. Potential
herb–drug interactions in community-dwelling older adults in China: the
Shanghai Aging Study. Aging Clinical and Experimental Research.
2020;32(12):2677-85.
58. Tan M, Win MT, Khan SAJAAMS. The use of complementary and
alternative medicine in chronic pain patients in Singapore: a
single-centre study. 2013;42(3):133-7.
59. Rosenberg EI, Genao I, Chen I, Mechaber AJ, Wood JA, Faselis CJ, et
al. Complementary and alternative medicine use by primary care patients
with chronic pain. 2008;9(8):1065-72.
60. Ha Y, Wang T, Li J, Li J, Lu R, Li J, et al. Herb–drug interaction
potential of licorice extract and paclitaxel: A pharmacokinetic study in
rats. 2020;45(2):257-64.
61. Zargaran A, Borhani-Haghighi A, Salehi-Marzijarani M, Faridi P,
Daneshamouz S, Azadi A, et al. Evaluation of the effect of topical
chamomile (Matricaria chamomilla L.) oleogel as pain relief in migraine
without aura: a randomized, double-blind, placebo-controlled, crossover
study. 2018;39(8):1345-53.
62. Mahboubi MJCTiCP. Mentha spicata as natural analgesia for treatment
of pain in osteoarthritis patients. 2017;26:1-4.
63. Djuv A, Nilsen OG, Steinsbekk AJBc, medicine a. The co-use of
conventional drugs and herbs among patients in Norwegian general
practice: a cross-sectional study. 2013;13(1):1-11.
64. Agbabiaka TB, Spencer NH, Khanom S, Goodman CJBJoGP. Prevalence of
drug–herb and drug–supplement interactions in older adults: a
cross-sectional survey. 2018;68(675):e711-e7.
65. McLay JS, Stewart D, George J, Rore C, Heys SDJEjocp. Complementary
and alternative medicines use by Scottish women with breast cancer.
What, why and the potential for drug interactions? 2012;68(5):811-9.
66. Kargozar R, Azizi H, Salari R. A review of effective herbal
medicines in controlling menopausal symptoms. Electron Physician.
2017;9(11):5826-33.
67. Pietrzyński Ł, Pysz-Waberski D, Pietrzyńska T, Kliber M, Gisterek
IJPMiP. Prevalence of complementary and alternative therapy use by
patients with advanced and metastatic cancer. 2022.